Humacyte, Inc.
HUMA · NASDAQ
Financial statements
Annual and quarterly income, balance-sheet, cash-flow and key-statistics data.
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2022 FY | 1.57M | -6.69M | -84.58M | -11.97M | -0.12 |
| 2023 FY | — | -76.55M | -100.05M | -110.78M | -1.07 |
| 2024 FY | — | -7.19M | -114.40M | -148.70M | -1.26 |
| 2025 FY | 2.04M | -15.01M | -107.44M | -40.83M | -0.26 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2022 FY | 204.30M | 87.37M | 149.77M | 50.07M | 116.93M |
| 2023 FY | 128.22M | 114.68M | 80.45M | 57.45M | 13.55M |
| 2024 FY | 137.87M | 190.54M | 44.94M | 16.54M | -52.67M |
| 2025 FY | 116.37M | 113.26M | 50.50M | 64.85M | 3.11M |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2022 FY | -71.13M | -1.05M | -72.18M | — | -67.73M |
| 2023 FY | -73.31M | -2.28M | -75.59M | — | -69.18M |
| 2024 FY | -98.12M | -1.57M | -99.69M | — | 14.49M |
| 2025 FY | -105.04M | -884.00K | -105.93M | — | -44.44M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2022 FY | 217.44M | 117.73M | — | — | — |
| 2023 FY | 293.71M | 270.72M | — | — | — |
| 2024 FY | 598.32M | 569.92M | — | — | — |
| 2025 FY | 151.91M | 166.26M | — | — | — |
| 2026-12-31 | — | — | — | — | — |
| 2027-12-31 | — | — | — | — | — |
| 2028-12-31 | — | — | — | — | — |
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 Q2 | 301.00K | -1.77M | -29.73M | -37.66M | -0.24 |
| 2025 Q3 | 753.00K | -1.37M | -24.39M | -17.51M | -0.11 |
| 2025 Q4 | 467.00K | -10.40M | -30.84M | -24.80M | -0.15 |
| 2026 Q1 | 495.00K | -1.54M | -28.94M | -17.62M | -0.09 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2025 Q2 | 138.80M | 134.74M | 38.03M | 83.96M | 4.05M |
| 2025 Q3 | 91.51M | 96.26M | 19.49M | 29.83M | -4.75M |
| 2025 Q4 | 116.37M | 113.26M | 50.50M | 64.85M | 3.11M |
| 2026 Q1 | 110.56M | 98.93M | 48.54M | 65.90M | 11.62M |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2025 Q2 | -26.41M | -568.00K | -26.98M | — | -24.96M |
| 2025 Q3 | -23.90M | -49.00K | -23.95M | — | -68.54M |
| 2025 Q4 | -26.12M | -39.00K | -26.16M | — | 31.01M |
| 2026 Q1 | -25.10M | -175.00K | -25.28M | — | -1.96M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2025 Q2 | 324.86M | 370.80M | — | — | — |
| 2025 Q3 | 275.47M | 285.80M | — | — | — |
| 2025 Q4 | 151.91M | 166.26M | — | — | — |
| 2026 Q1 | 120.03M | 137.40M | — | — | — |
| 2026-06-30 | — | — | — | — | — |
| 2026-09-30 | — | — | — | — | — |
| 2026-12-31 | — | — | — | — | — |